← Analyst Upside
AU · rank #4 · 2026-10-22
VIRP
PARIS · EUR · $3.25B (USD)
SignalStrong Buy4.7strength 4.7 / 10
verdict · PROCEED
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.634 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.21 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 4 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $410.75 | +18.9% |
| Momentum acceleration 3-month minus 12-month momentum. | +4.91% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.63 |
| Gross margin TTM | +67.2% |
| 52w high | $387.79 |
| Market cap (USD) | $3.25B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Virbac SA is a global animal-health company specializing in companion- and farm-animal pharmaceuticals, vaccines, endocrinology, and specialty veterinary diets.
Rationale
The analyst upside signal is supported by 100% EPS revision agreement and an 18.9% price target gap, validated by 9M 2026 revenue tracking at the upper end of full-year guidance.
Material risks
- 1Regulatory hurdles and toll-manufacturing supply constraints in North America could restrict product availability and impair regional growth momentum.
- 2Execution risk surrounding €125 million in industrial capex projects and the complex site transfer of Suprelorin manufacturing.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.
OpenAI
Proceed
Gemini
Proceed
Claude
Caution